People | Locations | Statistics |
---|---|---|
Naji, M. |
| |
Motta, Antonella |
| |
Aletan, Dirar |
| |
Mohamed, Tarek |
| |
Ertürk, Emre |
| |
Taccardi, Nicola |
| |
Kononenko, Denys |
| |
Petrov, R. H. | Madrid |
|
Alshaaer, Mazen | Brussels |
|
Bih, L. |
| |
Casati, R. |
| |
Muller, Hermance |
| |
Kočí, Jan | Prague |
|
Šuljagić, Marija |
| |
Kalteremidou, Kalliopi-Artemi | Brussels |
|
Azam, Siraj |
| |
Ospanova, Alyiya |
| |
Blanpain, Bart |
| |
Ali, M. A. |
| |
Popa, V. |
| |
Rančić, M. |
| |
Ollier, Nadège |
| |
Azevedo, Nuno Monteiro |
| |
Landes, Michael |
| |
Rignanese, Gian-Marco |
|
Gotuzzo, Eduardo
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (2/2 displayed)
- 2021Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Perucitations
- 2020Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazidcitations
Places of action
Organizations | Location | People |
---|
article
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in <jats:italic>M. tuberculosis</jats:italic> isolates susceptible to first-line drugs.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>There were 279 <jats:italic>M. tuberculosis</jats:italic> isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.</jats:p></jats:sec>